+65 3158 9940
1300 798 820
+64 9801 0299
Melbourne, Australia: Two Australian patients have undergone surgery with the aid of a new drug which assists neurosurgeons to visualise and remove high grade gliomas – brain tumours which typically have a poor prognosis. Neurosurgeons at Brisbane’s Wesley Hospital and the Royal Melbourne Hospital have pioneered the use of Gliolan® (5-aminolevulinic acid), describing it
Two and a half years ago, Melbourne based high flyer Shelli Whitehurst was diagnosed with Stage 4 breast cancer. The devastating diagnosis inspired her to found a business that’s now helping other cancer patients around the world. Shelli Whitehurst was at the pinnacle of her career, enjoying the success of the marketing business she founded
“I think the biggest revolutions in pancreas cancer treatment are yet to come.” Dr Lorraine Chantrill has been a medical oncologist for 10 years, with a particular focus on pancreatic cancer “because it is so terrible and there is so much room for improvement”. She notes that average survival rates for pancreas cancer have improved
“Oral mucositis is quite debilitating, because pain in your mouth, or ulceration in your mouth, makes it hard to eat and to swallow.” “Pretty much every cancer agent can cause some degree of mouth or gut damage. But it all depends on which drugs and what doses you are using. The range of incidence is
SARAH-JANE TASKER | THE AUSTRALIAN| MARCH 19, 2016 12:00AM From Big Pharma to Small Starts: Risking it All on a Life-Saving Cancer Drug to Win Bozena Zembrzuski and Carlo Montagner reflect on their decision to found Specialised Therapeutics and bring Abraxane to Australia. Picture: Aaron Francis After years working for big pharma in the US,
ICLUSIG will be listed for the treatment of the following patients: Chronic Myeloid Leukaemia (CML) patients who are resistant or intolerant to both nilotinib and dasatinib CML patients who are expressing the T315I mutation after prior TKI therapy Philadelphia positive Acute Lymphoblastic Leukaemia (Ph+ ALL) patients who are expressing the T315I mutation after prior therapy
Melbourne, January 2014 – A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.1 The updated OS data from the pivotal Phase III Metastatic Pancreatic Adenocarcinoma
Melbourne, June 2013 Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries. The company has become the inaugural donor for the Specialists Without Borders (SWB) organisation, an Australian based non-profit entity established in
Melbourne, November 2012 Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival. This is now the fourth disease in which ABRAXANE has demonstrated positive phase III results,
Melbourne, Australia May 2012: Patients with an aggressive form of brain tumour, glioblastoma multiforme (GBM), have been given access to a new brain tumour visualisation drug, Gliolan® (5-aminolevulinic acid), at The Royal Melbourne Hospital. In 2011, The Royal Melbourne Hospital trialled the drug with great success, and is expected to treat up to an additional 25